Pharmsintez reported for 2023 by RAS

Vladimir Petenyov
News editor
press@blackterminal.com
Pharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.
Pharmsynthes
Pharmsynthes
Review
  • BlackTerminal.com 2016 - 2026.